Literature DB >> 21095544

Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.

Joy E S Ardill1, Thomas M O'Dorisio.   

Abstract

Neuroendocrine tumors (NETs) are difficult to diagnose. Their symptoms may be vague or intermittent, and are frequently associated with much more common diseases; many of the tumors may be asymptomatic. Therefore, diagnosis can be delayed for some years. Because most NETs are secretory, the measurement of circulating biomarkers is helpful not only for diagnosis but also for assessing tumor response to treatment, monitoring disease progression, and use as prognostic indicators.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095544     DOI: 10.1016/j.ecl.2010.09.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

Review 1.  Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Authors:  Christian Fottner; Martina Ferrata; Matthias M Weber
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

2.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

3.  Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Authors:  Somer Matar; Anna Malczewska; Kjell Oberg; Lisa Bodei; Harry Aslanian; Anna Lewczuk-Myślicka; Pier Luigi Filosso; Alejandro L Suarez; Agnieszka Kolasińska-Ćwikła; Matteo Roffinella; Beata Kos-Kudła; Jarosław B Ćwikła; Ignat A Drozdov; Mark Kidd; Irvin M Modlin
Journal:  Neuroendocrinology       Date:  2019-04-16       Impact factor: 4.914

4.  Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Authors:  Paweł Gut; Agata Czarnywojtek; Jakub Fischbach; Maciej Bączyk; Katarzyna Ziemnicka; Elżbieta Wrotkowska; Maria Gryczyńska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.